Surgical Planning Associates, Inc.
$158.3K 28 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
US Implant Solutions, LLC
US Implant Solutions, LLC reported $157,122.73 across General Payments, Research, and Ownership to 162 physicians and teaching hospitals across 162 transactions.
- $157.1K
- All-tracks total
- 162
- Transactions
- 162
- Recipients
- +$99.5K
- General Payments vs PY2023
US Implant Solutions, LLC reported $157,122.73 across all CMS Open Payments tracks (General + Research + Ownership) to 162 physicians and teaching hospitals in Program Year 2024 - ranking #1073 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $157,122.73, averaging $969.89 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer us-implant-solutions-llc US Implant Solutions, LLC
$157.1K · #1073/1,925 · 0.0% industry · PY2024
- TOT $157.1K
- RANK #1073
- SHARE 0.0%
- TXN 162
- RCP 162
- CAT 3
- GEN $157.1K
- ΔGEN +$99.5K
- TOP1 10.6%
- PY 2024
Volume peers
Nearest volume peer: Surgical Planning Associates, Inc. ($158.3K)
US Implant Solutions, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
US Implant Solutions, LLC's CMS-reported General Payments increased by $99.5K (+172.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: US IMPLANT SOLUTIONS, LLCPY2023: US IMPLANT SOLUTIONS, LLCPY2024: US Implant Solutions, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $57,622.26
- PY2024
- $157,122.73
What the Data Shows for US Implant Solutions, LLC
Rank #1073 of 1,925 companies in CMS Open Payments for 2024 belongs to US Implant Solutions, LLC, which reported $157,122.73 across 162 transactions to 162 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $969.89 per transaction and $969.89 per recipient.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Travel and Lodging" at $136.4K, accounting for 86.8% of this company's General Payments and 36 transactions.
General Payment Breakdown by Type
"Travel and Lodging" leads US Implant Solutions, LLC's 3-category general-payment breakdown at $136.4K, 86.8% of the reported total.
How US Implant Solutions, LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $136.4K | 36 | 86.8% |
| Food and Beverage | $17.4K | 125 | 11.1% |
| Consulting Fee | $3.3K | 1 | 2.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $66,812.84 (42.5%) of $157,122.73 in this company's General Payments records across 47 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for US Implant Solutions, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Charles Moon
$16,643.87 across 7 reported transactions
- 2
Daniel Allison
$13,176.35 across 10 reported transactions
- 3
Daniel Horwitz
$12,985.60 across 8 reported transactions
- 4
Hans Van Lancker
$12,615.22 across 7 reported transactions
- 5
Erik Kubiak
$11,391.80 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as US Implant Solutions, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about US Implant Solutions, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with US Implant Solutions, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
NX Development Corp.
$158.5K 0 recipients
Compare payment profiles
Theragenics Corporation
$155.5K 65 recipients
Compare payment profiles
Micro-tech Endoscopy USA, Inc.
$159.3K 1,649 recipients
Compare payment profiles
Corcym Inc
$154.4K 495 recipients
Compare payment profiles
Outset Medical Inc
$160.7K 340 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.